LyphoMed's aerosol pentamidine
Executive Summary
Clinical trials for treatment of Pneumocytis carinii pneumonia (PCP) now have 30-40 patients in five New York area centers and are continuing to recruit more subjects. The company announced in an Aug. 31 press release that the five hospitals involved in the studies are seeking patients to enter the non-placebo controlled double blind studies in which each patient receives either aerosolized pentamidine or trimethoprim sulphamethoxazole (TMP/SMX) intravenously or orally. LyphoMed has ongoing studies for treatment and prophylaxis of PCP in centers nationwide, and has recently begun clinical studies for pediatriac applications of aerosol Pentam in one independent center and at the National Institutes for Allergy and Infectious Diseases.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.